Patents Assigned to Ocular Therapeutix, Inc.
  • Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
    Patent number: 11779536
    Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: October 10, 2023
    Assignee: Ocular Therapeutix, Inc.
    Inventors: Charles D. Blizzard, Rami El-Hayek, Michael Goldstein, Peter Jarrett, Andrew Vanslette
  • Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles
    Patent number: 11622935
    Abstract: The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.
    Type: Grant
    Filed: February 16, 2022
    Date of Patent: April 11, 2023
    Assignee: OCULAR THERAPEUTIX, INC.
    Inventors: Charles D. Blizzard, Ankita Desai, Arthur Driscoll, Michael Goldstein
  • Punctal plug and bioadhesives
    Patent number: 11559429
    Abstract: The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dry-eye using a bioadhesive without use of a punctal plug.
    Type: Grant
    Filed: September 24, 2022
    Date of Patent: January 24, 2023
    Assignee: OCULAR THERAPEUTIX, INC.
    Inventors: Noah Silverberg, Mark Silverberg
  • Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor
    Patent number: 11534396
    Abstract: This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: December 27, 2022
    Assignee: Ocular Therapeutix, Inc.
    Inventors: Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
  • Punctal plug and bioadhesives
    Patent number: 11458041
    Abstract: The present disclosure provides devices and methods for the treatment of ophthalmological conditions such as dry eye. Among the devices provided are punctal plugs and devices for inserting punctal plugs. The punctal plugs may be shaped for insertion in the punctum and/or the canaliculus. They may also be coated with a bioadhesive. Methods for inserting the punctal plugs are provided, as well as methods for preparing bioadhesive-coated punctal plugs. A method is also provided to treat dryeye using a bioadhesive without use of a punctal plug.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 4, 2022
    Assignee: Ocular Therapeutix, Inc.
    Inventors: Noah Silverberg, Mark Silverberg
  • Ocular implant containing a tyrosine kinase inhibitor
    Patent number: 11439592
    Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: September 13, 2022
    Assignee: Ocular Therapeutix, Inc.
    Inventors: Charles D. Blizzard, Arthur Driscoll, Rami El-Hayek, Michael Goldstein, Joseph Iacona, Peter Jarrett, Timothy S. Jarrett, Erica Kahn, Zachary Lattrell
  • Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
    Patent number: 11331267
    Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: May 17, 2022
    Assignee: Ocular Therapeutix, Inc.
    Inventors: Charles D. Blizzard, Rami El-Hayek, Michael Goldstein, Peter Jarrett, Andrew Vanslette
  • Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
    Patent number: 11291627
    Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: April 5, 2022
    Assignee: Ocular Therapeutix, Inc.
    Inventors: Charles D. Blizzard, Rami El-Hayek, Michael Goldstein, Peter Jarrett, Andrew Vanslette